Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Bristol-Myers Squibb Company ( BMY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.2%. By the end of trading, Bristol-Myers Squibb Company fell $0.76 (-1.6%) to $46.83 on heavy volume. Throughout the day, 21,406,953 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10,710,800 shares. The stock ranged in price between $46.40-$48.18 after having opened the day at $47.03 as compared to the previous trading day's close of $47.59. Other companies within the Drugs industry that declined today were: Rigel Pharmaceuticals ( RIGL), down 18.1%, Pluristem Therapeutic ( PSTI), down 14.4%, Vermillion ( VRML), down 13.0% and BioTime ( BTX), down 12.2%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $75.6 billion and is part of the health care sector. The company has a P/E ratio of 51.7, above the S&P 500 P/E ratio of 17.7. Shares are up 41.2% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Novogen ( NVGN), down 30.3%, Infinity Pharmaceuticals ( INFI), down 23.5%, Savient Pharmaceuticals ( SVNT), down 14.3% and Ampio Pharmaceuticals ( AMPE), down 12.6% , were all gainers within the drugs industry with Novo Nordisk A/S ( NVO) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.